GENI - Ticker AI Digest

Genincode PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (GENI) 1
GENI 06:01
Genincode PLC
Half-year Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of GENinCode Plc Half-Year Report (H1 2025)**
**Overview**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer risk, released its unaudited interim results for the six months ended 30 June 2025. The report highlights operational and financial progress, strategic initiatives, and future outlook.
**Operational Highlights**
**Commercial Contracts**Secured the first ROCA commercial contract with the NHS (University College London Hospitals and North Central London Cancer Alliance) for ovarian cancer risk surveillance.
**US Market Growth**Increased sales of LIPID inCode® and CARDIO inCode-Score® in the US, with over 40 clinics onboarded for CVD risk assessment.
**Regulatory Progress**Completed FDA De Novo Supervisory Review for CARDIO inCode-Score®, with agreement on outstanding deficiencies. Expects submission of additional data in Q1 2026.
**European Expansion**Growth in LIPID inCode® usage in Germany, Spain, and Italy, with CARDIO inCode-Score® pilots in Spain.
**Presentations**Showcased research at major cardiology conferences, emphasizing genetic modulation of cholesterol risk.
**Financial Highlights**
**Revenue Growth**First-half revenues increased by 15% to £1.60 million (H1 2024: £1.39 million), driven by growth in the UK, EU, and US.
**Fundraising**Successfully raised £3.7 million (gross £4.1 million) in March 2025 to support expansion.
**Adjusted EBITDA Loss**£2.07 million (H1 2024: £2.05 million), excluding unrealized forex loss.
**Cash Reserves**Increased to £2.44 million at 30 June 2025 (31 Dec 2024: £1.11 million).
**Outlook**
**Revenue Expectations**Full-year revenue revised to £3.3 million (lower than expected due to NHS restructuring and FDA delays).
**Strategic Focus**Expanding LIPID inCode® and CARDIO inCode-Score® in the US, EU, and UK.
**Regulatory Milestones**Aiming for FDA submission of CARDIO inCode-Score® in Q1 2026.
**Partnerships**Expanding collaborations in Germany, Spain, and with the NHS for ROCA ovarian cancer testing.
**CEO Statement**
Matthew Walls, CEO, emphasized increased revenues across core markets and progress in US regulatory pathways. However, NHS funding uncertainty and FDA delays impacted full-year revenue expectations. The company remains focused on commercial expansion, cost control, and strengthening its market presence.
**Financial Review**
**Revenue Breakdown**Spain remains the largest market, with 14% growth. UK sales increased to £383k, boosted by ROCA test sales.
**Gross Profit**Improved to £849k (H1 2024: £730k), with margins at 53.0%.
**Administrative Expenses**Slightly higher at £2.92 million due to inflationary pressures.
**Cash Flow**Operating cash outflow decreased to £3.22 million (H1 2024: £3.39 million).
**Conclusion**
GENinCode Plc demonstrated resilience in H1 2025, with revenue growth and strategic advancements despite regulatory and NHS-related challenges. The company is poised for further expansion, supported by its innovative genetic testing solutions and ongoing partnerships.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
GENI 06:01
Genincode PLC
NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company, has partnered with the North Central London (NCL) Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH) to launch the **Risk of Ovarian Cancer Algorithm (ROCA)** surveillance service. This marks the first NHS implementation of the ROCA <mark style="background-color:yellow">test</mark> outside of a trial setting, offering it as part of UCLHs Familial Cancer Clinic for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene mutations. The service aligns with new NICE guidance, providing an alternative to preventive surgery for women who wish to defer it, such as those planning to have children or avoid early menopause.
The ROCA test uses a proprietary algorithm to calculate individual risk based on factors like CA 125 blood test results, age, menopausal status, and BRCA gene alterations. Studies, including the UKFOCSS and ALDO trials, have shown a **44% reduction in late-stage ovarian cancer detections** with ROCA surveillance, improving treatment outcomes and reducing costs for the NHS. UCLHs initiative empowers eligible women across North Central London by closely monitoring their ovarian cancer risk, mitigating the likelihood of advanced-stage diagnoses.
Key stakeholders, including Professor Adam Rosenthal (UCLH), Ali Malik (NCL Cancer Alliance), and Matthew Walls (GENinCode CEO), highlighted the significance of this milestone in integrating innovative surveillance into clinical practice. GENinCode aims to extend the ROCA test to other NHS trusts in the future. The service is accessible via referrals to the UCLH Familial Cancer Clinic for patients with proven inherited BRCA gene alterations.
**Key Points**
First NHS implementation of ROCA test outside trials.
Targets women with BRCA1/BRCA2 mutations at high risk of ovarian cancer.
Reduces late-stage diagnoses by 44%improves outcomesand saves NHS costs.
Collaboration between GENinCodeUCLHand NCL Cancer Alliance.
Plans to expand to other NHS trusts.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
GENI 06:01
Genincode PLC
Half-year Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of GENinCode Plc Half-Year Report (H1 2025)**
**Overview**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer risk, released its unaudited interim results for the six months ended 30 June 2025. The report highlights operational and financial progress, strategic initiatives, and future outlook.
**Operational Highlights**
**Commercial Contracts**Secured the first ROCA commercial contract with the NHS (University College London Hospitals and North Central London Cancer Alliance) for ovarian cancer risk surveillance.
**US Market Growth**Increased sales of LIPID inCode® and CARDIO inCode-Score® in the US, with over 40 clinics onboarded for CVD risk assessment.
**Regulatory Progress**Completed FDA De Novo Supervisory Review for CARDIO inCode-Score®, with agreement on outstanding deficiencies. Expects submission of additional data in Q1 2026.
**European Expansion**Growth in LIPID inCode® usage in Germany, Spain, and Italy, with CARDIO inCode-Score® pilots in Spain.
**Presentations**Showcased research at major cardiology conferences, emphasizing genetic modulation of cholesterol risk.
**Financial Highlights**
**Revenue Growth**First-half revenues increased by 15% to £1.60 million (H1 2024: £1.39 million), driven by growth in the UK, EU, and US.
**Fundraising**Successfully raised £3.7 million (gross £4.1 million) in March 2025 to support expansion.
**Adjusted EBITDA Loss**£2.07 million (H1 2024: £2.05 million), excluding unrealized forex loss.
**Cash Reserves**Increased to £2.44 million at 30 June 2025 (31 Dec 2024: £1.11 million).
**Outlook**
**Revenue Expectations**Full-year revenue revised to £3.3 million (lower than expected due to NHS restructuring and FDA delays).
**Strategic Focus**Expanding LIPID inCode® and CARDIO inCode-Score® in the US, EU, and UK.
**Regulatory Milestones**Aiming for FDA submission of CARDIO inCode-Score® in Q1 2026.
**Partnerships**Expanding collaborations in Germany, Spain, and with the NHS for ROCA ovarian cancer testing.
**CEO Statement**
Matthew Walls, CEO, emphasized increased revenues across core markets and progress in US regulatory pathways. However, NHS funding uncertainty and FDA delays impacted full-year revenue expectations. The company remains focused on commercial expansion, cost control, and strengthening its market presence.
**Financial Review**
**Revenue Breakdown**Spain remains the largest market, with 14% growth. UK sales increased to £383k, boosted by ROCA test sales.
**Gross Profit**Improved to £849k (H1 2024: £730k), with margins at 53.0%.
**Administrative Expenses**Slightly higher at £2.92 million due to inflationary pressures.
**Cash Flow**Operating cash outflow decreased to £3.22 million (H1 2024: £3.39 million).
**Conclusion**
GENinCode Plc demonstrated resilience in H1 2025, with revenue growth and strategic advancements despite regulatory and NHS-related challenges. The company is poised for further expansion, supported by its innovative genetic testing solutions and ongoing partnerships.
Results 1
GENI 06:01
Genincode PLC
Notice of Results
Significant 0
No items for this category on selected date.
Speculation 1
GENI 09:43
Genincode PLC
Stmnt re Share Price Movement
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer (OC), issued a statement on September 17, 2025, addressing recent share price movements. The company stated it was unaware of any specific reasons for the sudden price fluctuations but reaffirmed its belief that the shares remain undervalued. GENinCode reconfirmed its trading and operational position from the August 26, 2025 update, highlighting ongoing progress in FDA De Novo discussions and efforts to address remaining deficiencies. Collaboration talks with a major distributor for potential U.S. and EU <mark style="background-color:yellow">test</mark> distribution are advancing. The company plans to provide further updates during its interim results announcement on September 30, 2025.
GENinCode specializes in genetic risk assessment for CVD, the leading global cause of death, and OC, with its ROCA test being a globally leading surveillance tool for early OC detection, particularly for BRCA gene mutation carriers. The ROCA test has received NICE guideline recommendation for OC surveillance. The company operates in the UK, Europe, and the U.S., leveraging clinical algorithms and AI bioinformatics to enhance patient risk assessment and preventive care.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
GENI 16:59
Genincode PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 5
GENI 06:01
Genincode PLC
Half-year Report
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of GENinCode Plc Half-Year Report (H1 2025)**
**Overview**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer risk, released its unaudited interim results for the six months ended 30 June 2025. The report highlights operational and financial progress, strategic initiatives, and future outlook.
**Operational Highlights**
**Commercial Contracts**Secured the first ROCA commercial contract with the NHS (University College London Hospitals and North Central London Cancer Alliance) for ovarian cancer risk surveillance.
**US Market Growth**Increased sales of LIPID inCode® and CARDIO inCode-Score® in the US, with over 40 clinics onboarded for CVD risk assessment.
**Regulatory Progress**Completed FDA De Novo Supervisory Review for CARDIO inCode-Score®, with agreement on outstanding deficiencies. Expects submission of additional data in Q1 2026.
**European Expansion**Growth in LIPID inCode® usage in Germany, Spain, and Italy, with CARDIO inCode-Score® pilots in Spain.
**Presentations**Showcased research at major cardiology conferences, emphasizing genetic modulation of cholesterol risk.
**Financial Highlights**
**Revenue Growth**First-half revenues increased by 15% to £1.60 million (H1 2024: £1.39 million), driven by growth in the UK, EU, and US.
**Fundraising**Successfully raised £3.7 million (gross £4.1 million) in March 2025 to support expansion.
**Adjusted EBITDA Loss**£2.07 million (H1 2024: £2.05 million), excluding unrealized forex loss.
**Cash Reserves**Increased to £2.44 million at 30 June 2025 (31 Dec 2024: £1.11 million).
**Outlook**
**Revenue Expectations**Full-year revenue revised to £3.3 million (lower than expected due to NHS restructuring and FDA delays).
**Strategic Focus**Expanding LIPID inCode® and CARDIO inCode-Score® in the US, EU, and UK.
**Regulatory Milestones**Aiming for FDA submission of CARDIO inCode-Score® in Q1 2026.
**Partnerships**Expanding collaborations in Germany, Spain, and with the NHS for ROCA ovarian cancer testing.
**CEO Statement**
Matthew Walls, CEO, emphasized increased revenues across core markets and progress in US regulatory pathways. However, NHS funding uncertainty and FDA delays impacted full-year revenue expectations. The company remains focused on commercial expansion, cost control, and strengthening its market presence.
**Financial Review**
**Revenue Breakdown**Spain remains the largest market, with 14% growth. UK sales increased to £383k, boosted by ROCA test sales.
**Gross Profit**Improved to £849k (H1 2024: £730k), with margins at 53.0%.
**Administrative Expenses**Slightly higher at £2.92 million due to inflationary pressures.
**Cash Flow**Operating cash outflow decreased to £3.22 million (H1 2024: £3.39 million).
**Conclusion**
GENinCode Plc demonstrated resilience in H1 2025, with revenue growth and strategic advancements despite regulatory and NHS-related challenges. The company is poised for further expansion, supported by its innovative genetic testing solutions and ongoing partnerships.
GENI 06:01
Genincode PLC
NHS (UCLH) Risk of Ovarian Cancer (ROCA) launch
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company, has partnered with the North Central London (NCL) Cancer Alliance and University College London Hospitals NHS Foundation Trust (UCLH) to launch the **Risk of Ovarian Cancer Algorithm (ROCA)** surveillance service. This marks the first NHS implementation of the ROCA <mark style="background-color:yellow">test</mark> outside of a trial setting, offering it as part of UCLHs Familial Cancer Clinic for women at high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene mutations. The service aligns with new NICE guidance, providing an alternative to preventive surgery for women who wish to defer it, such as those planning to have children or avoid early menopause.
The ROCA test uses a proprietary algorithm to calculate individual risk based on factors like CA 125 blood test results, age, menopausal status, and BRCA gene alterations. Studies, including the UKFOCSS and ALDO trials, have shown a **44% reduction in late-stage ovarian cancer detections** with ROCA surveillance, improving treatment outcomes and reducing costs for the NHS. UCLHs initiative empowers eligible women across North Central London by closely monitoring their ovarian cancer risk, mitigating the likelihood of advanced-stage diagnoses.
Key stakeholders, including Professor Adam Rosenthal (UCLH), Ali Malik (NCL Cancer Alliance), and Matthew Walls (GENinCode CEO), highlighted the significance of this milestone in integrating innovative surveillance into clinical practice. GENinCode aims to extend the ROCA test to other NHS trusts in the future. The service is accessible via referrals to the UCLH Familial Cancer Clinic for patients with proven inherited BRCA gene alterations.
**Key Points**
First NHS implementation of ROCA test outside trials.
Targets women with BRCA1/BRCA2 mutations at high risk of ovarian cancer.
Reduces late-stage diagnoses by 44%improves outcomesand saves NHS costs.
Collaboration between GENinCodeUCLHand NCL Cancer Alliance.
Plans to expand to other NHS trusts.
GENI 16:59
Genincode PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
GENI 09:43
Genincode PLC
Stmnt re Share Price Movement
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GENinCode Plc, a UK-based predictive genetics company focused on preventing cardiovascular disease (CVD) and ovarian cancer (OC), issued a statement on September 17, 2025, addressing recent share price movements. The company stated it was unaware of any specific reasons for the sudden price fluctuations but reaffirmed its belief that the shares remain undervalued. GENinCode reconfirmed its trading and operational position from the August 26, 2025 update, highlighting ongoing progress in FDA De Novo discussions and efforts to address remaining deficiencies. Collaboration talks with a major distributor for potential U.S. and EU <mark style="background-color:yellow">test</mark> distribution are advancing. The company plans to provide further updates during its interim results announcement on September 30, 2025.
GENinCode specializes in genetic risk assessment for CVD, the leading global cause of death, and OC, with its ROCA test being a globally leading surveillance tool for early OC detection, particularly for BRCA gene mutation carriers. The ROCA test has received NICE guideline recommendation for OC surveillance. The company operates in the UK, Europe, and the U.S., leveraging clinical algorithms and AI bioinformatics to enhance patient risk assessment and preventive care.
GENI 06:01
Genincode PLC
Notice of Results

AI Crunch

Single-Ticker AI Crunch
GENI signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Genincode PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full GENI AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for GENI on 2025-09-30.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
9273096
Enterprise Value
35432408
Public Float
20.06
Broker Target
7.5
Shares Out
725027042
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
None
Market
None
Sector
Gas, Water and Multi-utilities
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-09-23
Net Debt
-876000.0
Cash
1110000.0
EPS
-0.02
Net Income
-4434000.0
Revenue
2701000.0
Enterprise Value
35432408
Trailing PE
-
Forward PE
-
Price Sales TTM
3.1823
Price Book MRQ
3.0629
EV Revenue
2.0057
EV EBITDA
-3.1541

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
42.4898
Institutions As Of
2026-04-15
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
3
Sale TR1
6
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit GENI.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-09-30 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Genincode PLC has fresh news flow feeding the chart narrative.
AI Charts Studio
GENI Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-09-30 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -25.83%
RSI Gauge
Price Change
AI Forecast